This site is intended for US Residents only.
Important Safety InformationPrescribing InformationMedication GuideHealthcare Professionals Site

Care partners play a critical role for people with AML

Staying resilient often takes a team effort

As your loved one gets started on treatment with KOMZIFTI, you may have initial questions about what their day-to-day routines may look like. Common questions from care partners like you are listed below.

Common questions

KOMZIFTI is used to treat adults with AML with an NPM1 mutation whose AML has come back or did not improve after previous treatment(s) and who have no other satisfactory treatment options. The doctor will determine if your loved one is eligible for KOMZIFTI.

You shouldn't have to worry about the cost of the medicine. Kura is committed to helping eligible patients access appropriate financial support. There may be financial support options available depending on the type of insurance you have. Learn how Kura RxKonnect™ can help.

Differentiation syndrome is a serious condition that can be life-threatening or lead to death if not treated. It can happen as early as 3 days after you start KOMZIFTI treatment and can also happen later during treatment with KOMZIFTI.

Call the doctor or take your loved one to the nearest hospital emergency room right away if they develop any of the following signs or symptoms of differentiation syndrome during treatment with KOMZIFTI: fever, joint or bone pain, dizziness, shortness of breath or trouble breathing, cough, chest pain, rapid weight gain, rash, decreased urine output, swelling of the hands, feet, ankles, or legs.

If your loved one develops signs and symptoms of differentiation syndrome during treatment with KOMZIFTI, the doctor may temporarily stop KOMZIFTI and give your loved one a corticosteroid medicine. The doctor will monitor your loved one until their signs and symptoms improve. See additional Important Safety Information below.

KOMZIFTI can cause serious side effects including QT prolongation, which is changes in the electrical activity of the heart that may lead to irregular heartbeats (rhythm) that can be life-threatening or lead to death. Tell the healthcare provider right away if your loved one feels faint, lightheaded, dizzy, or has shortness of breath, or if their heart is beating irregularly or fast during treatment. The most common side effects of KOMZIFTI include infections (including bacterial infections), bleeding, diarrhea, nausea, feeling tired, swelling in the arms and legs, muscle, bone, and joint pain, itching, fever with decreased white blood cell counts, and changes in liver function tests. See additional Important Safety Information below

Advise your loved one to talk to their doctor, who may decrease their dose, temporarily stop, or completely stop their treatment with KOMZIFTI if they develop certain side effects. You are encouraged to report side effects of prescription drugs to FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

In a clinical study, the median time to first response was 2.7 months in patients who achieved CR or CRh. 88% of patients who achieved CR or CRh did so within 6 months of starting treatment.

Their doctor will determine how long they should stay on treatment. KOMZIFTI is recommended to be taken for at least 6 months if their AML is not progressing or they're not experiencing unacceptable side effects.

Your loved one will have regular checkups with their doctor, who may perform tests or exams to determine whether KOMZIFTI is working.

At the discretion of the doctor, the doctor will inform you or your friend or loved one when they should come to the office for checkups regarding their treatment with KOMZIFTI.

Support

There may be financial support options available for appropriate patients:

  • Commercially insured patient copay support

    Eligible commercially insured patients may pay as little as $0 for their prescription each month. Terms and conditions will apply.

  • Independent foundations

    Independent foundations may be able to support patients with out-of-pocket costs. Contact Kura RxKonnect™ to learn more.

  • Patient Assistance Program

    Eligible patients who do not have insurance coverage may qualify for free medicine from Kura’s Patient Assistance Program (PAP). Apply to learn more.

Although you may want to support your loved one as much as possible, it’s important to also take care of yourself so you don’t feel overwhelmed and can be at your best to help your loved one.

  • Do only those things your loved one can’t do.

    If they are still capable of doing certain activities, such as paying bills or cooking meals, encourage them to do so. Having a level of independence will make them feel better about being in a care-receiving situation.

  • Be prepared to do what you promise to do.

    Many care recipients find it emotionally difficult to depend on others, and many worry about being a burden. With all these mixed feelings, they need to be able to rely on you. Do what you promise. Remember that they need you, even if they don't say so.

  • Take care of yourself.

    Care partners often exhaust themselves by trying to handle responsibilities on top of normal daily routines. Providing care for a loved one while holding down a job, and perhaps taking care of a family, can lead to exhaustion. If you become exhausted, you’re more likely to make bad decisions or to take your frustrations out on your loved one. Take time out to do things you enjoy. Care partners who take time for themselves can be there for the long haul.

  • Give yourself a break.

    At some point in your role as a care partner, you may start to feel resentment toward your responsibilities or even your loved one, especially if you are a long-term care partner. These thoughts may be followed by feelings of guilt. Caregiving is a difficult job, so don’t beat yourself up over these normal and common feelings.

  • Remember that your family and close friends are your first resource.

    There can be deep emotional currents when a loved one becomes ill. Some family members will want to do everything, while others will do very little unless they’re asked. Spouses, children, siblings, other relatives, and friends can do a lot to ease your burden. Don’t be afraid to reach out to them for help.

Curious about a term or definition?

What is KOMZIFTI?

KOMZIFTI is a prescription medicine used to treat adults with acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM1) mutation whose AML has come back or did not improve after previous treatment(s) and who have no other satisfactory treatment options.

Your healthcare provider will perform a test to make sure that KOMZIFTI is right for you.

It is not known if KOMZIFTI is safe and effective in children.

Please see full Prescribing Information, including Boxed WARNING, and Medication Guide for additional information.

Important Safety Information

What is the most important information I should know about KOMZIFTI?

KOMZIFTI can cause serious side effects including:Differentiation Syndrome: Differentiation syndrome is a condition that affects your blood cells that is common during treatment with KOMZIFTI and can be life-threatening or lead to death if not treated. Differentiation syndrome can happen as early as 3 days after you start KOMZIFTI treatment and can also happen later during treatment with KOMZIFTI. Tell your healthcare provider or go to the nearest hospital emergency room right away if you develop any of the following signs or symptoms of differentiation syndrome during treatment with KOMZIFTI:

  • fever
  • joint or bone pain
  • dizziness
  • shortness of breath or trouble breathing
  • cough
  • chest pain
  • rapid weight gain
  • rash
  • decreased urine output
  • swelling of hands, feet, ankles, or legs

If you develop signs and symptoms of differentiation syndrome during treatment with KOMZIFTI, your healthcare provider may temporarily stop KOMZIFTI and give you a corticosteroid medicine. Your healthcare provider will monitor you until your signs and symptoms improve.

Changes in electrical activity of your heart (QT prolongation).
Changes in the electrical activity of your heart may lead to irregular heartbeats (rhythm) that can be life-threatening or lead to death. Your healthcare provider will check the electrical activity of your heart with a test called an electrocardiogram (ECG) and will also do blood tests to check your potassium and magnesium levels before and during treatment with KOMZIFTI. Tell your healthcare provider right away if you feel faint, lightheaded, or dizzy, or if you have shortness of breath, or if you feel your heart beating irregularly or fast during treatment with KOMZIFTI.

Before taking KOMZIFTI, tell your healthcare provider about all of your medical conditions, including if you:

  • have any heart problems, including a condition called long QT syndrome.
  • have problems with abnormal levels of salts in your blood (electrolytes), such as potassium and magnesium levels.
  • are pregnant or plan to become pregnant. KOMZIFTI can harm your unborn baby.
  • Females who are able to become pregnant:
    • Your healthcare provider will perform a pregnancy test before you start treatment with KOMZIFTI.
    • Use effective birth control (contraception) during treatment with KOMZIFTI and for 6 months after the last dose.
  • Males who have female partners who are able to become pregnant:
    • Use effective birth control (contraception) during treatment with KOMZIFTI and for 3 months after the last dose.
    • Talk to your healthcare provider about birth control methods you can use during this time.
  • are breastfeeding or plan to breastfeed. It is not known if KOMZIFTI passes into your breast milk. Do not breastfeed during your treatment with KOMZIFTI and for 2 weeks after your last dose.

Tell your healthcare provider about any other medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

KOMZIFTI and other medicines may affect each other causing side effects. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist.

The most common side effects of KOMZIFTI include:

  • infections including bacterial infections
  • bleeding
  • diarrhea
  • nausea
  • feeling tired
  • swelling in the arms and legs
  • muscle, bone, and joint pain
  • itching
  • fever with decreased white blood cell counts
  • changes in liver function tests

Your healthcare provider may decrease your dose, temporarily stop, or completely stop your treatment with KOMZIFTI if you develop certain side effects during treatment with KOMZIFTI.

KOMZIFTI may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

These are not all the possible side effects of KOMZIFTI. Call your doctor for medical advice about side effects.

You are encouraged to report side effects of prescription drugs to FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

What is KOMZIFTI?

KOMZIFTI is a prescription medicine used to treat adults with acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM1) mutation whose AML has come back or did not improve after previous treatment(s) and who have no other satisfactory treatment options.

Your healthcare provider will perform a test to make sure that KOMZIFTI is right for you.

It is not known if KOMZIFTI is safe and effective in children.

Please see full Prescribing Information, including Boxed WARNING, and Medication Guide for additional information.

Important Safety Information

What is the most important information I should know about KOMZIFTI?

KOMZIFTI can cause serious side effects including:Differentiation Syndrome: Differentiation syndrome is a condition that affects your blood cells that is common during treatment with KOMZIFTI and can be life-threatening or lead to death if not treated. Differentiation syndrome can happen as early as 3 days after you start KOMZIFTI treatment and can also happen later during treatment with KOMZIFTI. Tell your healthcare provider or go to the nearest hospital emergency room right away if you develop any of the following signs or symptoms of differentiation syndrome during treatment with KOMZIFTI:

  • fever
  • joint or bone pain
  • dizziness
  • shortness of breath or trouble breathing
  • cough
  • chest pain
  • rapid weight gain
  • rash
  • decreased urine output
  • swelling of hands, feet, ankles, or legs

If you develop signs and symptoms of differentiation syndrome during treatment with KOMZIFTI, your healthcare provider may temporarily stop KOMZIFTI and give you a corticosteroid medicine. Your healthcare provider will monitor you until your signs and symptoms improve.

Changes in electrical activity of your heart (QT prolongation).
Changes in the electrical activity of your heart may lead to irregular heartbeats (rhythm) that can be life-threatening or lead to death. Your healthcare provider will check the electrical activity of your heart with a test called an electrocardiogram (ECG) and will also do blood tests to check your potassium and magnesium levels before and during treatment with KOMZIFTI. Tell your healthcare provider right away if you feel faint, lightheaded, or dizzy, or if you have shortness of breath, or if you feel your heart beating irregularly or fast during treatment with KOMZIFTI.

Before taking KOMZIFTI, tell your healthcare provider about all of your medical conditions, including if you:

  • have any heart problems, including a condition called long QT syndrome.
  • have problems with abnormal levels of salts in your blood (electrolytes), such as potassium and magnesium levels.
  • are pregnant or plan to become pregnant. KOMZIFTI can harm your unborn baby.
  • Females who are able to become pregnant:
    • Your healthcare provider will perform a pregnancy test before you start treatment with KOMZIFTI.
    • Use effective birth control (contraception) during treatment with KOMZIFTI and for 6 months after the last dose.
  • Males who have female partners who are able to become pregnant:
    • Use effective birth control (contraception) during treatment with KOMZIFTI and for 3 months after the last dose.
    • Talk to your healthcare provider about birth control methods you can use during this time.
  • are breastfeeding or plan to breastfeed. It is not known if KOMZIFTI passes into your breast milk. Do not breastfeed during your treatment with KOMZIFTI and for 2 weeks after your last dose.

Tell your healthcare provider about any other medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

KOMZIFTI and other medicines may affect each other causing side effects. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist.

The most common side effects of KOMZIFTI include:

  • infections including bacterial infections
  • bleeding
  • diarrhea
  • nausea
  • feeling tired
  • swelling in the arms and legs
  • muscle, bone, and joint pain
  • itching
  • fever with decreased white blood cell counts
  • changes in liver function tests

Your healthcare provider may decrease your dose, temporarily stop, or completely stop your treatment with KOMZIFTI if you develop certain side effects during treatment with KOMZIFTI.

KOMZIFTI may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

These are not all the possible side effects of KOMZIFTI. Call your doctor for medical advice about side effects.

You are encouraged to report side effects of prescription drugs to FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.